Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief.

Zydus had approached the Supreme Court challenging the Delhi High Court's order, which prevented the company from producing and marketing breast cancer drug Sigrima.

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in the market in response to a plea moved by a Swiss pharmaceutical major.

The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents the sale of its breast cancer drug, Sigrima. Swiss pharmaceutical giant,